


## IN THE CLAIMS

Claims 1-37 (previously cancelled)

38 (currently amended): A method for inhibiting bone metastases from prostate cancer in a patient having prostate cancer which comprises human comprising administering thereto to the patient a therapeutically effective amount of a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

39 (original): The method of Claim 38 wherein the bone metastases are osteoblastic.

42 (currently amended): The method of Claim 40 38 which additionally comprises administering an anticancer drug.

43 (original): The method of Claim 42 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

44 (currently amended): The method of Claim 40 38 which additionally comprises administering radiation.


45 (currently amended): The method of Claim 40 38 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

46 (original): The method of Claim 45 wherein the therapeutic agent is a bisphosphonate.

56 (cancelled)

59-64 (canceled)

65 (amended): A method for inhibiting metastatic growth from prostate cancer in a patient having prostate cancer which comprises administering thereto to the patient a therapeutically effective amount of a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

66 (original): The method of Claim 65 wherein the bone metastases are metastatic growth is osteoblastic metastatic growth.

67 (original): The method of Claim 65 which additionally comprises administering an anticancer drug.


68 (original): The method of Claim 67 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

69 (original): The method of Claim 65 which additionally comprises administering radiation.

70 (original): The method of Claim 65 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

71 (original): The method of Claim 70 wherein the therapeutic agent is a bisphosphonate.

72 (new): A method for inhibiting osteoblastic bone metastases from prostate cancer in a human comprising administering thereto a therapeutically effective amount of a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

73 (new): The method of Claim 72 which additionally comprises administering an anticancer drug.

74 (new): The method of Claim 73 wherein the anticancer drug is selected from


the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

75 (new): The method of Claim 72 which additionally comprises administering radiation.

76 (new): The method of Claim 72 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

77 (original): The method of Claim 76 wherein the therapeutic agent is a bisphosphonate.

78 (new): A method for inhibiting osteoblastic metastatic growth from prostate cancer in a human comprising administering thereto a therapeutically effective amount of a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

79 (new): The method of Claim 78 which additionally comprises administering an anticancer drug.

80 (new): The method of Claim 79 wherein the anticancer drug is selected from


the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

81 (new): The method of Claim 78 which additionally comprises administering radiation.

82 (new): The method of Claim 78 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

83 (original): The method of Claim 82 wherein the therapeutic agent is a bisphosphonate.

84 (new): A method for inhibiting bone metastases from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III



III.

85 (new): The method of Claim 84 wherein the bone metastases are osteoblastic.

86 (new): The method of Claim 84 which additionally comprises administering an anticancer drug.

87 (new): The method of Claim 86 wherein the anticancer drug is selected from


the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

88 (new): The method of Claim 84 which additionally comprises administering radiation.

89 (new): The method of Claim 84 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

90 (new): The method of Claim 89 wherein the therapeutic agent is a bisphosphonate.

91 (new): A method for inhibiting metastatic growth from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III



III.

92 (new): The method of Claim 91 wherein the metastatic growth is osteoblastic metastatic growth.

93 (new): The method of Claim 91 which additionally comprises administering an anticancer drug.


94 (new): The method of Claim 93 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

95 (new): The method of Claim 91 which additionally comprises administering radiation.

96 (new): The method of Claim 91 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

97 (new): The method of Claim 96 wherein the therapeutic agent is a bisphosphonate.

98 (new): A method for inhibiting osteoblastic bone metastases from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III



III.

99 (new): The method of Claim 98 which additionally comprises administering an anticancer drug.

100 (new): The method of Claim 99 wherein the anticancer drug is selected from


the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

101 (new): The method of Claim 98 which additionally comprises administering radiation.

102 (new): The method of Claim 98 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

103 (new): The method of Claim 102 wherein the therapeutic agent is a bisphosphonate.

104 (new): A method for inhibiting osteoblastic metastatic growth from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III



III.

105 (new): The method of Claim 104 which additionally comprises administering an anticancer drug.

106 (new): The method of Claim 105 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin

D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

107 (new): The method of Claim 104 which additionally comprises administering radiation.

108 (new): The method of Claim 104 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

109 (new): The method of Claim 108 wherein the therapeutic agent is a bisphosphonate.